drugset / Trial / NCT03029429

Theophylline Treatment for Pseudohypoparathyroidism

NCT03029429

Phase 2 Active not recruiting 29 enrolled Vanderbilt University Medical Center Harvard University · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Pseudohypoparathyroidism is a genetic disorder with limited treatment options. Patients have early-onset obesity, short stature and increased risk of type 2 diabetes. This phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. The investigators hypothesize that theophylline will cause weight loss, improve glucose tolerance and slow growth plate closure in children and young adults.

Timeline

Start
2018-09-01
Primary completion
2026-12-01
Completion
2026-12-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Theophylline Small molecule Oral